Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Denali starts DNL747 dosing in Phase Ib Alzheimer’s trial

Brain inflammation from Alzheimer’s disease. Credit: National Institute on Aging, NIH.



  • Denali starts DNL747 dosing in Phase Ib Alzheimer’s trial

Go Top